Shots:
- Aristea to receive $60M as up front and $10M as equity investment in Aristea’s Series B financing. Arena gets an exclusive option to acquire Aristea, including rights to all CXCR2 programs, post completion of the P-IIb study of RIST4721 in PPP
- The companies can jointly explore the development of additional neutrophil-mediated diseases, including HS & IBD to generate multiple data during the option period. The collaboration allows Arena to bolster its early- to mid-stage immunology pipeline in its core therapeutic areas
- RIST4721 has completed its P-IIa study and is on track to be evaluated in P-IIb. Additionally, Aristea reported the closing of a $63M in Series B funding
Click here to read full press release/ article | Ref: Businesswire | Image: PR Newswire
The post Arena and Aristea Collaborate to Develop RIST4721 for Treatment of Complicated Immune-Mediated Inflammatory Diseases first appeared on PharmaShots.
